Three‐dimensional analysis of systematic biopsy‐derived prostate cancer upgrading over targeted biopsy: Potential of target margin and surrounding region sampling using magnetic resonance–ultrasound image fusion systems

2020 ◽  
Author(s):  
Yoh Matsuoka ◽  
Sho Uehara ◽  
Soichiro Yoshida ◽  
Hajime Tanaka ◽  
Minato Yokoyama ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Magnetic Resonance ◽  
Image Fusion ◽  
Dimensional Analysis ◽  
Three Dimensional ◽  
Ultrasound Image ◽  
Targeted Biopsy ◽  
Fusion Systems ◽  
Systematic Biopsy

Detection of prostate cancer using magnetic resonance imaging/ultrasonography image-fusion targeted biopsy in African-American men

2017 ◽  
Vol 120 (2) ◽  
pp. 233-238 ◽  
Author(s):  
Toshitaka Shin ◽  
Thomas B. Smyth ◽  
Osamu Ukimura ◽  
Nariman Ahmadi ◽  
Andre Luis de Castro Abreu ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Prostate Cancer ◽  
African American ◽  
Magnetic Resonance ◽  
Image Fusion ◽  
African American Men ◽  
Targeted Biopsy ◽  
Resonance Imaging

scholarly journals Magnetic Resonance Imaging-targeted Biopsy Versus Systematic Biopsy in the Detection of Prostate Cancer: A Systematic Review and Meta-analysis

2019 ◽  
Vol 76 (3) ◽  
pp. 284-303 ◽  
Author(s):  
Veeru Kasivisvanathan ◽  
Armando Stabile ◽  
Joana B. Neves ◽  
Francesco Giganti ◽  
Massimo Valerio ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Prostate Cancer ◽  
Systematic Review ◽  
Magnetic Resonance ◽  
Meta Analysis ◽  
Targeted Biopsy ◽  
Resonance Imaging ◽  
Systematic Biopsy

scholarly journals Evidence-based guideline recommendations on multiparametric magnetic resonance imaging in the diagnosis of prostate cancer: A Cancer Care Ontario clinical practice guideline

2017 ◽  
Vol 11 (1-2) ◽  
pp. 1 ◽  
Author(s):  
Masoom A. Haider ◽  
Xiaomei Yao ◽  
Andrew Loblaw ◽  
Antonio Finelli
Keyword(s):  
Magnetic Resonance Imaging ◽  
Prostate Cancer ◽  
Magnetic Resonance ◽  
Practice Guideline ◽  
Elevated Risk ◽  
Cochrane Library ◽  
Targeted Biopsy ◽  
Resonance Imaging ◽  
Multiparametric Magnetic Resonance Imaging ◽  
Systematic Biopsy

This clinical guideline focuses on: 1) the use of multiparametric magnetic resonance imaging (mpMRI) in diagnosing clinically significant prostate cancer (CSPC) in patients with an elevated risk of CSPC and who are biopsy-naïve; and 2) the use of mpMRI in diagnosing CSPC in patients with a persistently elevated risk of having CSPC and who have a negative transrectal ultrasound (TRUS)-guided systematic biopsy.The methods of the Practice Guideline Development Cycle were used. MEDLINE, EMBASE, the Cochrane Library (1997‒April 2014), main guideline websites, and relevant annual meeting abstracts (2011‒2014) were searched. Internal and external reviews were conducted.The two main recommendations are:Recommendation 1: In patients with an elevated risk of CSPC (according to prostate-specific antigen [PSA] levels and/or nomograms) who are biopsy-naïve: mpMRI followed by targeted biopsy (biopsy directed at cancer-suspicious foci detected with mpMRI) should not be considered the standard of care; data from future research studies are essential and should receive high-impact trial funding to determine the value of mpMRI in this clinical context.Recommendation 2:In patients who had a prior negative TRUS-guided systematic biopsy and demonstrate an increasing risk of having CSPC since prior biopsy (e.g., continued rise in PSA and/or change in findings from digital rectal examination): mpMRI followed by targeted biopsy may be considered to help in detecting more CSPC patients compared with repeated TRUS-guided systematic biopsy.

scholarly journals Magnetic resonance/ultrasound fusion targeted biopsy of the prostate can be improved by adding systematic biopsy

2021 ◽  
Author(s):  
Victor Mihail Cauni ◽  
Dan Stanescu ◽  
Florin Tanase ◽  
Bogdan Mihai ◽  
Cristian Persu
Keyword(s):  
Prostate Cancer ◽  
Magnetic Resonance ◽  
Cancer Detection ◽  
Detection Rate ◽  
Specific Antigen ◽  
Cancer Detection Rate ◽  
Targeted Biopsy ◽  
Detection Rates ◽  
Clinically Significant ◽  
Systematic Biopsy

Aim: Magnetic resonance/ ultrasound fusion targeted biopsy (Tbs) is widely used for diagnosing prostate cancer (PCa). The aim of our study was to compare the cancer detection rate (CDR) and the clinically significant prostate cancer detection rate (csPCa) of the magnetic resonance/ultrasound fusion targeted biopsy with those of the standard systematic biopsy (Sbs) and of the combination of both techniques.Material and methods: A total of 182 patients underwent magnetic resonance/ultrasound fusion Tbs on the prostate for PCa suspicion based on multiparametric magnetic resonance imaging (mMRI) detection of lesions with PI-RADSv2 score ≥3. A total of 78 patients had prior negative biopsies. Tb was performed by taking 2-4 cores from each suspected lesion, followed by Sb with 12 cores. We evaluated the overall detection rate of PCa and clinically significant prostate cancer, defined as any PCa with Gleason score ≥3+4.Results: Median prostate specific antigen (PSA) level pre-biopsy was 7.4 ng/ml and median free-PSA/PSA ratio was 10.2%. Patient median age was 62 years old. PIRADSv2 score was 3 in 54 cases, 4 in 96 cases and 5 in 32 cases. PI-RADS-dependent detection rate of Tbs for scores 3, 4 and 5 was 25.9%, 65.6% and 84.4%, respectively, with csPCa detection rates of 24.1%, 54.2%, and 71.9%. Overall detection rate was 57.1% for Tbs, which increased to 60.4% by adding Sbs results. Detection rate for clinically significant prostate cancer (csPCa) was 48.4% and increased to 51.1% by adding Sbs. Overall detection rate for repeated biopsy was 50% and 68.3% for biopsy in naïve patients. Sbs detection rate was 55.5%, 8 patients having a negative biopsy on Tbs.Conclusions: When Tbs is considered due to a PI-RADS ≥3 lesion on mMRI, combined Tbs + Sbs increases the overall CDR and csPCa detection rates.

scholarly journals Role of Multiparametric Magnetic Resonance in the study of the Prostate

2020 ◽  
Author(s):  
Troncone Raffaella ◽  
Coda Marco ◽  
Aliberti Daniele ◽  
Ciccone Vincenzo ◽  
Carbone Mattia
Keyword(s):  
Magnetic Resonance Imaging ◽  
Prostate Cancer ◽  
Magnetic Resonance ◽  
Study Protocol ◽  
Sagittal Plane ◽  
Ultrasound Image ◽  
Functional Study ◽  
Targeted Biopsy ◽  
Resonance Imaging ◽  
Weighted Sequences

Magnetic resonance imaging is the fastest and least invasive diagnostic method for the study of the prostate. The method's multiparametricity allows the acquisition of the images highlighting different characteristics in relation to the different sampling sequences. In particular, the MRI investigation plays a role in: • risk stratification and staging of the tumor, therefore active surveillance • detection of prostate cancer; • localization and characterization of prostate cancer before performing a procedure (pre-biopsy, pre-surgery, or radiation therapy); • procedural guide (targeted biopsy guide). The study protocol includes T2-weighted sequences on an axial and sagittal plane, diffusion-weighted sequences for the functional study (DWI) with high b values, contrast dynamic sequences (DCE-MRI), T1-weighted sequences with a large FOV. The study protocol here presented follows the latest PI-RADS v2.1 guidelines. The axial scan plans are acquired according to the anatomical axis of the gland. In our protocol we add a further neutral T2 weighing, a sequence that will be subsequently used for the coupling of images with fusion techniques, such as target-biopsy. The adoption of PI-RAADS v2.1, the most recent update of the system, improves the assessment of intra-patient injury variability and simplifies the general assessment of the prostate in magnetic resonance imaging. The magnetic resonance examination thus obtained allows the correct overlap of the lesion anatomy with the ultrasound image TRUS acquired with the Fusion technique, used for targeted biopsy sampling.

Sign in / Sign up

Export Citation Format

Share Document